ethyl tropane-3-carboxylate | 155600-93-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: ethyl tropane-3-carboxylate
• 英文别名: Ethyl 8-methyl-8-azabicyclo[3.2.1]octane-3-carboxylate
• CAS: 155600-93-4
• 化学式: C₁₁H₁₉NO₂
• 分子量: 197.277
• InChiKey: FKPQVXMRGGHFMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-甲氧基苄基氨基)乙腈 、 ethyl tropane-3-carboxylate 在 lithium diisopropyl amide 作用下， 生成 1'-Benzyl-8-methylspiro[8-azabicyclo[3.2.1]octane-3,3'-azetidine]-2'-one
  参考文献：
  名称：

  Synthesis of a new series of 2,7-diazaspiro[3.5]nonan-1-ones and study of their cholinergic properties

  摘要：

  A new series of substituted 2,7-diazaspiro[3.5]nonan-1-ones (la-1), structurally related to the muscarinic agonist RS-86, has been synthesized and tested for cholinergic properties both in vitro and in vivo. None of the compounds showed significant cholinergic properties at either the central or peripheral level. A possible explanation for the lack of activity is given.

  DOI：

  10.1016/0223-5234(94)90207-0
• 作为产物：
  描述：

  Tropanol 在 盐酸 、 氯化亚砜 作用下， 以 乙醇 、 氯仿 、 水 为溶剂， 反应 21.0h， 生成 ethyl tropane-3-carboxylate
  参考文献：
  名称：

  Synthesis of a new series of 2,7-diazaspiro[3.5]nonan-1-ones and study of their cholinergic properties

  摘要：

  A new series of substituted 2,7-diazaspiro[3.5]nonan-1-ones (la-1), structurally related to the muscarinic agonist RS-86, has been synthesized and tested for cholinergic properties both in vitro and in vivo. None of the compounds showed significant cholinergic properties at either the central or peripheral level. A possible explanation for the lack of activity is given.

  DOI：

  10.1016/0223-5234(94)90207-0

文献信息

• [EN] INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE<br/>[FR] INHIBITEURS DE LA FORME INDUCTIBLE DE LA 6-PHOSPHOFRUCTOSE-2-KINASE
  申请人：EXELIXIS INC

  公开号：WO2012149528A1

  公开（公告）日：2012-11-01

  The invention is directed to inhibitors of inducible form of 6-phosphofructose-2-kinase of formula I, as well as to pharmaceutically acceptable salts of formula I, and pharmaceutical compositions comprising a compound of formula I. The compounds can be used to treat cancer.

  该发明涉及公式I的可诱导形式6-磷酸果糖-2-激酶的抑制剂，以及公式I的药用可接受盐，以及包含公式I化合物的药物组合物。这些化合物可用于治疗癌症。
• Ion channel modulators and methods of use
  申请人：Martinborough Esther

  公开号：US20060160817A1

  公开（公告）日：2006-07-20

  In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.

  一般而言，这项发明涉及作为离子通道调节剂有用的化合物。现在已经发现，本发明的化合物及其药用合成物可作为电压门控钠通道和/或钙通道的抑制剂。
• Modulators of muscarinic receptors
  申请人：Makings R. Lewis

  公开号：US20060079505A1

  公开（公告）日：2006-04-13

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及肌动蛋白受体的调节剂。本发明还提供了包含这种调节剂的组合物，并提供了使用这种组合物治疗肌动蛋白受体介导的疾病的方法。
• Ion Channel Modulators and Methods of Uses
  申请人：Martinborough Esther

  公开号：US20100184753A1

  公开（公告）日：2010-07-22

  In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.

  通常，本发明涉及作为离子通道调节剂有用的化合物。现已发现，本发明的化合物及其药学上可接受的组合物可用作电压门控钠通道和/或钙通道的抑制剂。
• ION CHANNEL MODULATORS AND METHODS OF USE
  申请人：MARTINBOROUGH ESTHER

  公开号：US20120270318A1

  公开（公告）日：2012-10-25

  In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.

  一般地，本发明涉及用作离子通道调节剂的化合物。现已发现，本发明的化合物及其药学上可接受的组合物可用作电压门控钠通道和/或钙通道的抑制剂。